drugset
drugset / Trial / NCT01359605

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

NCT01359605 ↗

Phase 1 Completed 6 enrolled Anthera Pharmaceuticals
NaSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to characterize the metabolism and excretion (ADME) of a single oral dose of \[14C\]varespladib methyl.

Timeline

Start
2011-06
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Varespladib Methyl Small molecule 500 mg Oral

Indications

No indication recorded.